The modified Rankin scale (mRS), a clinician-reported measure of global disability, is widely applied for evaluating stroke patient outcomes and as an end point in randomized clinical trials. Multiple types of evidence support its validity and reliability. The reported data support the view that the mRS is a valuable instrument for assessing the impact of new stroke treatments. A useful document on how to Training, questions and scoring is available.
|Modified Rankin Scale|
|0||No symptoms at all|
|1||No significant disability despite symptoms; able to carry out all usual duties and activities|
|2||Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance|
|3||Moderate disability; requiring some help, but able to walk without assistance|
|4||Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance|
|5||Severe disability; bedridden, incontinent and requiring constant nursing care and attention|
Assessing Clinical Outcome
A good clinical outcome is a measure of neurologic functional with a score of 0-2 on the modified Rankin scale assessed 90 days after treatment. This does not exclude clinically significant benefit in patients in whom an mRS score of 2 is not achieved.